Posts

ARPA-H commits up to $125 million to on-demand personalized RNA medicines

ARPA-H is awarding up to $125 million to five teams through its Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. The initiative aims to create automated, distributed systems that can produce personalized RNA-based genetic medicines—including treatments for cancer, rare diseases, and gene-editing applications—at or near the point of care. Funded teams include Centillion Biosciences, HDT Bio, Massachusetts General Hospital, the University of Utah, and Waterfall Scientific. The platforms are designed to integrate DNA/RNA synthesis, RNA production, lipid-nanoparticle formulation, fill-finish, and rapid quality-control testing. One University of Utah system aims to enable lot release in as little as one day. Waterfall Scientific received up to $54.5 million to lead a consortium developing a continuous-flow, cell-free mRNA manufacturing and characterization platform. ARPA-H says personalized therapies currently can take months to manufacture, cost hun...

UK regulator halts Tavneos sales

Fierce AI Innovation Awards 2026: Winners Announced

BioSpace webinar highlights future-proofing manufacturing partnerships

DualityBio and Genentech Sign Potentially $1B+ ADC Collaboration

Roche licenses Simcere’s trispecific T-cell engager in deal worth up to $1.53 billion

GSK advances newer mRNA flu-vaccine formulation to Phase 3

Regeneron May Weigh Expanded Sanofi Partnership, RBC Says

Weave Bio and Takeda Expand AI Automation Across Drug-Development Regulatory Workflows

Wainua failure sharpens—but does not settle—the TTR silencer versus stabilizer debate

GSK advances dual-target mRNA flu vaccine to Phase III

Alumis plans biomarker-focused Phase III lupus trial after LUMUS miss

Novartis’ Rhapsido scores two Phase III wins in relapsing MS